United Theraputics ends esuberaprost trial early
The company kept the announcement short, but said the study did not meet its primary endpoint.
9th April 2019
Latest news
GSK’s HIV drug Dovato gets FDA approval
It marks the first two-drug complete regimen for HIV-infected patients.
9th April 2019
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD's Lenvima and UCB's Cimzia.
9th April 2019
Pfizer's Ibrance extended for use in men by FDA
Pfizer's Ibrance will now be available to male patients with metastatic breast cancer.
8th April 2019
CPI, GSK, AZ to establish wet granulation manufacturing facility
The facility will be based at CPI’s existing space at NETPark, County Durham.
8th April 2019
‘Use greener asthma inhalers’, encourages NICE
The decision aid also says that all used inhalers should be returned to local pharmacies for environmentally safe disposal.
8th April 2019
Cancer patients to benefit from £6 million AI investment
The new £6 million investment will help to further the development of Mirada’s state of the art software algorithms and imaging applications.
8th April 2019
Sanofi ends option phase of rare disease alliance with Alnylam
Through the agreement Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease.
8th April 2019
Categories refined for the 2019 PharmaTimes Sales Awards
The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector.
5th April 2019
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
5th April 2019
AZ’s Fasenra shows promise in hypereosinophilic syndrome
The drug is AstraZeneca’s first respiratory biologic.
5th April 2019
Myriad, AstraZeneca and MSD expand collaboration
The expansion will use BRACAnalysis CDx to identify germline BRCA mutations.
5th April 2019
EU approves new dosing schedule for MSD’s Keytruda
The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals.
5th April 2019
HPV vaccine to thank for 89% decline in cervical cancer
The authors of the study also highlighted a “herd immunity” benefit, as a drop in disease among unvaccinated women was observed.
5th April 2019
Brexit will have ‘minimal’ effect on R&D in UK, says expert
The NIHR's Dr Jonathan Sheffield gave a positive outlook on UK R&D post-Brexit at the 'Brexit: What's Next for Pharma?’ PING conference.
4th April 2019
